Moreover, in the secretome of ALL-MSCs in remission, COL1A2 is reduced relative to D-MSCs (Log2FC = −2.37, p = 0.007) and AML-MSCs in remission (Log2FC = −1.77, p = 0.038). This evidence concerns the gene COL1A2 and acute myeloid leukemia.